<DOC>
	<DOCNO>NCT00191893</DOCNO>
	<brief_summary>The purpose study assess effect 24 month treatment daily teriparatide injection ( recombinant human PTH [ 1-34 ] ) 20 microgram bone histomorphometry architecture . Patients include postmenopausal , osteoporotic woman treat long term ( least 36 month ) alendronate , well postmenopausal , osteoporotic woman never treat osteoporosis .</brief_summary>
	<brief_title>Bone Effects Teriparatide Following Alendronate</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Diagnosis Osteoporosis : Pretreated patient currently osteoporotic osteopenic . Treatmentnaive patient currently osteoporotic Pretreated patient least 36 month treatment alendronate Na 10 mg/day 70 mg/week . Treatmentnaive patient significant osteoporosis treatment prior 36 month , assess investigator History bone metabolic disease , Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis , hyperparathyroidism ( uncorrected ) , intestinal malabsorption . History malignant neoplasm prior 5 year , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . If malignant neoplasm ever diagnose , patient must presently free disease .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>